ArticleJournal of immunology (Baltimore, Md. : 1950)2020
Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Temporal Dissection of TGF-β signaling reveals differential impact during female reproductive mucosal CD8 resident memory T cell differentiation.Mucosal immunology · 2026Article
- IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma.Journal for immunotherapy of cancer · 2026Article
- IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?Journal of translational autoimmunity · 2025Review
- Article
- Visualizing cellular interactions: intravital imaging in tumor microenvironment.Frontiers in immunology · 2025Review
- Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer.Molecular therapy. Nucleic acids · 2024Article
- Epithelial organoid supports resident memory CD8 T cell differentiation.Cell reports · 2024Article
- Applications of Intravital Imaging in Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2024Review
- Tumor-Infiltrating Lymphocytes and Adoptive Cell Therapy: State of the Art in Colorectal, Breast and Lung Cancer.Physiological research · 2023Review
- Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.Cell reports. Medicine · 2023Article
- Tumor therapeutic response monitored by telemetric temperature sensing, a preclinical study on immunotherapy and chemotherapy.Scientific reports · 2023Article
- Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer.Journal for immunotherapy of cancer · 2023Review
- Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.Exploration of targeted anti-tumor therapy · 2023Review
- Antitumor Activities of Interleukin-12 in Melanoma.Cancers · 2022Review
- P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.Cancer immunology research · 2022Article
- Knowns and Unknowns about CAR-T Cell Dysfunction.Cancers · 2022Review
- Role of the tumor immune microenvironment in tumor immunotherapy.Oncology letters · 2022Review
- Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.Frontiers in oncology · 2022Review
- A cellular census of human peripheral immune cells identifies novel cell states in lung diseases.Clinical and translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Optimal ex vivo expansion protocols of tumor-specific T cells followed by adoptive cell therapy must yield T cells able to home to tumors and effectively kill them. Our previous study demonstrated ex vivo activation in the presence of IL-12-induced optimal CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.